Repare Shareholders Approve Acquisition by XenoTherapeutics, Inc.
Gilead Sciences to acquire Repare's RP-3467 [Yahoo! Finance]
Repare Therapeutics Announces Acquisition of Pol? ATPase Inhibitor, RP-3467, by Gilead Sciences for Up To $30 Million in Total Consideration
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Repare Therapeutics Inc. (Nasdaq – RPTX), Axalta Coating Systems Ltd. (NYSE – AXTA), Blue Foundry Bancorp (Nasdaq – BLFY), Golden Entertainment, Inc (Nasdaq - GDEN)
Halper Sadeh LLC Encourages RPTX, AXTA, BLFY, GDEN Shareholders to Contact the Firm to Discuss Their Rights